Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 6/20 | 0.47 |
| ▸ | F10 | P00742 | 6/20 | 0.47 |
| ▸ | PLG | P00747 | 6/20 | 0.47 |
| ▸ | PLAU | P00749 | 6/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.47 |
| ▸ | PLAT | P00750 | 5/20 | 0.47 |
| ▸ | HPN | P05981 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 4/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903497 | 0.89 | CYP19A1 (0.50) | CYP19A1FFAR1F2F10PLG | |
| SCHEMBL903531 | 0.89 | CYP19A1 (0.50) | CYP19A1FFAR1F2F10PLG | |
| SCHEMBL11474936 | 0.88 | CYP19A1 (0.61) | CYP19A1FFAR1F2F10PLG | |
| SCHEMBL17422783 | 0.82 | CYP19A1 (0.71) | CYP19A1FFAR1IDO1CHEK1ASIC3 | |
| SCHEMBL12698675 | 0.81 | CYP19A1 (0.56) | CYP19A1FFAR1F2F10PLG | |
| SCHEMBL19889776 | 0.78 | CDK5 (0.51) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL18845618 | 0.78 | KDM4E (0.62) | CYP19A1FFAR1F2F10PLG | |
| SCHEMBL18817905 | 0.78 | HPN (0.53) | CYP19A1F2F10PLGPLAU | |
| SCHEMBL18817932 | 0.78 | HPN (0.53) | CYP19A1F2F10PLGPLAU | |
| SCHEMBL903395 | 0.78 | CYP19A1 (0.49) | CYP19A1FFAR1F2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2621279-B1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180065985-A1 | PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS | MERCK SHARPE & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170334926-A1 | PROCESS FOR PREPARING SUBSTITUTED INDOLE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334926-A1 | PROCESS FOR PREPARING SUBSTITUTED INDOLE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9725464-B2 | Process for preparing tetracyclic heterocycle compounds | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725464-B2 | Process for preparing tetracyclic heterocycle compounds | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2012050848-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012041227-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040924-A1 | FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP19A1 3552/4885FFAR1 3561/4885F2 3782/4885 |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP19A1 3552/4885FFAR1 3561/4885F2 3782/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | CYP19A1 3552/4885FFAR1 3561/4885F2 3782/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP19A1 3552/4885FFAR1 3561/4885F2 3782/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CYP19A1 3552/4885FFAR1 3561/4885F2 3782/4885 |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, ZC3HAV1L | CYP19A1 596/4885FFAR1 1955/4885F2 232/4885 |
| US-20170334926-A1 | PROCESS FOR PREPARING SUBSTITUTED INDOLE COMPOUNDS | IDO1, IDO2, TPH1 | CYP19A1 173/4885FFAR1 1940/4885F2 1264/4885 |
| US-20180065985-A1 | PROCESS FOR MAKING TETRACYCLIC HETEROCYCLE COMPOUNDS | CYP1B1, CYP1A2, CYP2F1 | CYP19A1 54/4885FFAR1 4144/4885F2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.